US20020052309A1 - Method of treating endothelial injury - Google Patents

Method of treating endothelial injury Download PDF

Info

Publication number
US20020052309A1
US20020052309A1 US08/712,358 US71235896A US2002052309A1 US 20020052309 A1 US20020052309 A1 US 20020052309A1 US 71235896 A US71235896 A US 71235896A US 2002052309 A1 US2002052309 A1 US 2002052309A1
Authority
US
United States
Prior art keywords
endothelial
chemotherapeutic agent
epo
erythropoietin
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/712,358
Other languages
English (en)
Inventor
Athanasius A. Anagnostou
George Sigounas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24861777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020052309(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US08/712,358 priority Critical patent/US20020052309A1/en
Assigned to EAST CAROLINA UNIVERSITY reassignment EAST CAROLINA UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANAGNOSTOU, ATHANASIUS A., SIGOUNAS, GEORGE
Priority to US08/842,700 priority patent/US5922674A/en
Priority to CN97199338A priority patent/CN1113669C/zh
Priority to AT97940974T priority patent/ATE282425T1/de
Priority to PCT/US1997/015966 priority patent/WO1998010650A1/en
Priority to JP10513794A priority patent/JP2001503028A/ja
Priority to ES97940974T priority patent/ES2231889T3/es
Priority to DE69731652T priority patent/DE69731652T2/de
Priority to DK97940974T priority patent/DK0933995T3/da
Priority to PT97940974T priority patent/PT933995E/pt
Priority to EP97940974A priority patent/EP0933995B8/en
Priority to HK00101826.8A priority patent/HK1022810B/xx
Priority to CA002265547A priority patent/CA2265547C/en
Priority to US09/525,797 priority patent/US7531501B1/en
Publication of US20020052309A1 publication Critical patent/US20020052309A1/en
Priority to CNB021506884A priority patent/CN1250281C/zh
Priority to US11/771,470 priority patent/US7803408B2/en
Priority to JP2008048009A priority patent/JP2008133305A/ja
Priority to JP2009086240A priority patent/JP2009196999A/ja
Priority to US12/509,841 priority patent/US20090285908A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to the use of human erythropoietin (EPO) in the prevention or treatment of endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer).
  • EPO human erythropoietin
  • the present invention further relates to the use of EPO in conjunction with chemotherapy.
  • EPO Erythropoietin
  • erythrogenesis red blood cell production
  • EPO stimulates the division and differentiation of committed erythroid progenitors in the bone marrow.
  • Normal plasma erythropoietin levels range from 0.01 to 0.03 Units/mL, and can increase up to 100 to 1,000-fold during hypoxia or anemia.
  • Recombinant human erythropoietin (rHuEpo or epoetin alfa) is commercially available Epogen® (Amgen Inc., Thousand Oaks, Calif.) and as Procrit® (Ortho Biotech Inc., Raritan, N.J.). EPO is indicated for treatment of anemia, including anemias associated with cancer chemotherapy, chronic renal failure, malignancies, adult and juvenile rheumatoid arthritis, disorders of haemoglobin synthesis, prematurity, and zidovudine treatment of HIV infection.
  • Epogen® Amgen Inc., Thousand Oaks, Calif.
  • Procrit® Ortho Biotech Inc., Raritan, N.J.
  • the vascular endothelium is a layer of cells lining the inner vascular wall and in direct contact with blood, providing an active natural barrier between the circulatory and extravascular compartment.
  • the endothelium is involved in signal and information transfer at the cellular, tissue and organ level, and plays a role in both cell-mediated and humoral immune responses.
  • Endothelial cells are metabolically active and normally produce a number of substances with effects on the vascular lumen and on platelets.
  • Endothelial vasodilators include prostacyclin (PGI 2 ) and endothelium-derived relaxing factor (EDRF, which may be nitric oxide or a more stable adduct thereof); these two substances also act to inhibit platelet aggregation.
  • GM-CSF granulocyte macrophage-colony stimulating factor
  • G-CSF granulocyte-colony stimulating factor
  • Interleukin-3 IL-3 also enhances the proliferation of these cells. See Bussolino et al., Nature 337:471 (1989); Brizzi et al., J. Clin. Invest. 91:2887 (1993).
  • a first aspect of the present invention is a method of reducing endothelial injury caused by a chemotherapeutic agent, by administering an endothelial-protecting amount of erythropoietin in conjunction with the administration of the chemotherapeutic agent.
  • the endothelial-protecting amount of erythropoietin may be administered simultaneously with the chemotherapeutic agent, prior to the chemotherapeutic agent, or after the chemotherapeutic agent.
  • a second aspect of the present invention is a method of enhancing endothelial cell inhibition in a subject treated with a chemotherapeutic agent, by administering an endothelial-inhibiting amount of erythropoietin in conjunction with the chemotherapeutic agent.
  • the endothelial-inhibiting amount of erythropoietin may be administered simultaneously with, prior to, or after the chemotherapeutic agent.
  • a further aspect of the present invention is a method of treating a solid vascularized tumor by administering an antineoplastic chemotherapeutic agent in conjunction with an endothelial-inhibiting amount of erythropoietin.
  • the endothelial-inhibiting amount of erythropoietin may be administered simultaneously with, prior to, or after the chemotherapeutic agent.
  • a further aspect of the present invention is a method of treating endothelial injury caused by mechanical damage, exposure to radiation, inflammation, heart disease or cancer by administering an endothelial-protecting amount of erythropoietin to a subject in need of such treatment.
  • FIG. 1 is a graph showing the dose-response curve for viability of endothelial cells after exposure to cisplatin.
  • FIG. 2 is a graph showing the responses of endothelial cell cultures exposed simultaneously to cisplatin and varying dosages of EPO, compared to control endothelial cell cultures exposed only to cisplatin.
  • FIG. 3 is a graph showing the responses of endothelial cell cultures exposed first to cisplatin and, two hours later, to varying dosages of EPO (compared to control endothelial cell cultures exposed only to cisplatin).
  • FIG. 4 is a graph showing the responses of endothelial cell cultures exposed first to varying dosages of EPO and, two hours later, to cisplatin (compared to control endothelial cell culture exposed only to cisplatin).
  • EPO erythropoietin
  • EPO can effectively prevent and/or repair endothelial damage caused by chemotherapeutic agents.
  • administration of EPO concomitantly with chemotherapeutic agents produces a biphasic response: certain doses of EPO protect endothelial cells from the deleterious effects of the chemotherapeutic agent, while increased doses enhance the endothelial growth-suppression caused by the chemotherapeutic agent.
  • EPO EPO to enhance endothelial growth-suppression during chemotherapy is useful in treating angiogenic tumors, where it is desirable to prevent or slow the formation of new blood vessels which support tumor growth.
  • Tumors require an adequate blood supply, and growth of new vessels in the tumor mass is stimulated by angiogenic factors secreted by tumor tissue.
  • inhibition of angiogenesis in tumor tissue has been shown to cause tumor regression.
  • Highly vascularized solid tumors include cerebellar hemangioblastoma, ductal carcinoma of the breast, and squamous cell cancer of the larynx.
  • Abnormal angiogenesis is involved in additional pathological conditions, including diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.
  • the ability of EPO to reduce or prevent abnormal angiogenesis will be of use in preventing or reducing angiogenesis associated with such disease states.
  • One method according to the present invention is the use of EPO as an adjunct in the chemotherapy of neoplastic disease.
  • EPO is provided in endothelial-protecting amounts where protection of the endothelium from the adverse effects of chemotherapeutic agents is desired.
  • a second method according to the present invention is the use of EPO as an adjunct in the chemotherapy of neoplastic disease, where enhancement of the adverse effects of chemotherapeutic agents on endothelium (e.g., enhancement of endothelial growth suppression) is desired. In such situations, EPO is provided in endothelial-inhibiting amounts.
  • endothelial-protecting amounts of EPO refer to those dosages which reduce or prevent the suppression of endothelial growth which would otherwise occur due to exposure to a chemotherapeutic agent or radiation, mechanical trauma, or a disease state known to damage the endothelium.
  • an endothelial-protecting amount of EPO may be defined as those dosages which increase the numbers of viable endothelial cells following exposure to the chemotherapeutic agent or radiation, mechanical trauma, or a disease state known to damage the endothelium; the increased number of viable cells is in comparison to that which would be expected in the absence of EPO.
  • the most effective endothelial-protecting amounts of EPO may vary depending upon the time of administration and the etiology of endothelial damage.
  • EPO endothelial damage
  • the most effective endothelial-protecting amounts of EPO will vary depending upon whether EPO is administered simultaneously with, prior to, or after, the chemotherapeutic agent, and may vary depending upon the specific chemotherapeutic agent in question.
  • endothelial-inhibiting amounts of EPO refer to those dosages which enhance or increase the suppression of endothelial growth which would otherwise occur due to exposure to a chemotherapeutic agent or radiation, mechanical trauma, or a disease state known to damage the endothelium.
  • an endothelial-inhibiting amount of EPO may be defined as those dosages which decrease the numbers of viable endothelial cells following exposure to the chemotherapeutic agent or radiation, mechanical trauma, or a disease state known to damage the endothelium; the decreased number of viable cells is in comparison to that which would be expected in the absence of EPO.
  • the most effective endothelial-inhibiting amounts of EPO may vary depending upon the time of administration and the etiology of endothelial damage.
  • EPO endothelial damage is due to exposure to a chemotherapeutic agent
  • the most effective inhibiting amounts of EPO will vary depending upon whether EPO is administered simultaneously with, prior to, or after, the chemotherapeutic agent, and may vary depending upon the specific chemotherapeutic agent in question.
  • Endothelial damage may be assessed by a reduction in the proliferation of endothelial cells and/or decreased numbers of viable endothelial cells, leading to a total decrease in the number of viable endothelial cells. Such a decrease in the number of viable endothelial cells may also be referred to as endothelial growth suppression, or endothelial cell suppression or inhibition.
  • a method of reducing endothelial injury in a subject caused by administration of a chemotherapeutic agent to the subject refers to a method which reduces or prevents the decrease in viable endothelial cells which would otherwise be caused by administration of the chemotherapeutic agent.
  • a method of enhancing endothelial cell inhibition in a subject caused by administration of a chemotherapeutic agent to the subject refers to a method which increases or enhances the reduction in viable endothelial cells which would otherwise be caused by administration of the chemotherapeutic agent.
  • Damage to endothelial cells may also be caused by radiation therapy, mechanical trauma, and by disease states such as inflammation, heart disease (e.g., atherosclerosis) and cancer.
  • atherosclerosis for example, injury to or dysfunction of the endothelium leads to reduced vasodilator response and to increased platelet deposition on the arterial wall.
  • Serotonin and thromboxane A 2 released from deposited platelets cause arterial constriction and spasm, increase adhesion and aggregation of platelets, and enhance the atherosclerotic process.
  • the consequences of coronary obstruction are often ameliorated by the formation of new coronary vessels in response to angiogenic stimuli.
  • EPO EPO to enhance endothelial growth and/or repair, or to prevent endothelial damage, will be a useful adjunct in treating endothelial damage due to mechanical damage, radiation therapy, or due to disease states which adversely affect the endothelium.
  • human erythropoietin refers to both the naturally occurring human erythropoietin glycoprotein as well as recombinant human erythropoietin (rHuEpo or epoetin alfa, available commercially as Epogen® (Amgen Inc., Thousand Oaks, Calif.) and as Procrit® (Ortho Biotech Inc., Raritan, N.J.)).
  • Epogen® Amgen Inc., Thousand Oaks, Calif.
  • Procrit® Ortho Biotech Inc., Raritan, N.J.
  • Peptide analogs of EPO may also be used in the methods of the present invention.
  • peptide analogs are those compounds which, while not having amino acid sequences identical to that of EPO, have a similar three-dimensional structure.
  • EPO receptor peptide ligands Peptides which mimic the biological activity of erythropoietin may be substituted for EPO in the methods of the present invention.
  • the sequence of such peptides may represent fragments of the full-length EPO protein sequence, which fragments are capable of binding to and activating the EPO receptor.
  • peptides with sequences dissimilar to that of EPO may be utilized in the methods of the present invention, where such peptides mimic the biological activity of EPO.
  • chemotherapeutic agent refers to cytotoxic antineoplastic agents, that is, chemical agents which preferentially kill neoplastic cells or disrupt the cell cycle of rapidly proliferating cells, used therapeutically to prevent or reduce the growth of neoplastic cells.
  • Chemotherapeutic agents are also known as antineoplastic drugs or cytotoxic agents, and are well known in the art.
  • chemotherapy includes treatment with a single chemotherapeutic agent or with a combination of agents. In a subject in need of treatment, chemotherapy may be combined with surgical treatment or radiation therapy, or with other antineoplastic treatment modalities.
  • chemotherapeutic agents are vinca alkaloids, epipodophyllotoxins, anthracycline antibiotics, actinomycin D, puromycin, gramicidin D, paclitaxel (Taxol®, Bristol Myers Squibb), colchicine, cytochalasin B, emetine, maytansine, and amsacrine (or “mAMSA”).
  • the vinca alkaloid class is described in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 1277-1280 (7th ed. 1985) (hereafter “Goodman and Gilman”).
  • Exemplary of vinca alkaloids are vincristine, vinblastine, and vindesine.
  • the epipodophyllotoxin class is described in Goodman and Gilman, supra at 1280-1281.
  • Exemplary of epipodophyllotoxins are etoposide, etoposide orthoquinone, and teniposide.
  • the anthracycline antibiotic class is described in Goodman and Gilman, supra at 1283-1285.
  • Exemplary of anthracycline antibiotics are daunorubicin, doxorubicin, mitoxantraone, and bisanthrene.
  • Actinomycin D also called Dactinomycin
  • Plicamycin also called mithramycin, is described in Goodman and Gilman, supra at 1287-1288.
  • Additional chemotherapeutic agents include cisplatin (Platinol®, Bristol Myers Squibb); carboplatin (ParaPlatin®, Bristol Myers Squibb); mitomycin (Mutamycu®, Bristol Myers Squibb); altretamine (Hexalen®, U.S. Bioscience, Inc.); cyclophosphamide (Cytoxan®, Bristol Myers Squibb); lomustine [CCNU] (CeeNU®, Bristol Myers Squibb); carmustine [BCNU] (BiCNU®, Bristol Myers Squibb).
  • chemotherapeutic drugs vary depending upon the specific agent used, as would be known to one skilled in the art. Depending upon the agent used, chemotherapeutic agents may be administered, for example, by injection (intravenously, intramuscularly, intraperitoneally, subcutaneously, intratumor, intrapleural) or orally.
  • the administration of a compound “in conjunction with” a second compound means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other.
  • the two compounds may be administered simultaneously (concurrently) or sequentially.
  • Simultaneous administration may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
  • Subjects to be treated by the method of the present invention include both human and animal (e.g., dog, cat, cow, horse) subjects, and are preferably mammalian subjects.
  • Neoplasms which are the most susceptible to chemotherapy are those with a high percentage of cells in the process of division, including but not limited to breast, liver, brain, lung, and ovarian cancer.
  • Highly vascularized solid tumors are amenable to treatment with endothelial-inhibiting amounts of EPO in conjunction with chemotherapeutic agents, as these tumors rely on angiogenesis to provide adequate blood supply to the growing tumor tissue.
  • EPO used according to the methods of the present invention may be administered by any suitable means, as would be apparent to one skilled in the art.
  • EPO may be administered systemically (e.g., intravenously) or locally (e.g., injected into a tumor, tissues immediately surrounding a tumor, or into an anatomic compartment containing a tumor).
  • an endothelial-inhibiting amount of EPO is utilized as an adjunct to chemotherapy, the EPO may be administered locally to a tumor (or the immediately surrounding tissue) in which it is desirable to prevent angiogenesis.
  • a chemotherapeutic agent is delivered systemically, for example, an endothelial-protecting amount of EPO may be administered systemically by intravenous injection.
  • EPO EPO
  • the dosage and timing of EPO administration used in conjunction with a chemotherapeutic agent will similarly depend upon the desired effect.
  • the present inventors have discovered that depending upon the timing of EPO administration (simultaneous with, before, or after chemotherapeutic agent administration) and the dosage of EPO, EPO either protects the endothelium from the growth-inhibiting effects of chemotherapeutic agents, or enhances the endothelial growth inhibition seen with chemotherapeutic agents. It will be apparent to those skilled in the art how to determine, by routine experimentation, the dosage and timing of EPO administration in conjunction with a particular chemotherapeutic agent to achieve a desired effect.
  • EPO is administered in an endothelial-protecting amount. Suitable endothelial-protecting dosages may range from about 100 U/kg to about 200 U/kg.
  • EPO is administered in an endothelial-inhibiting amount which may range from about 750 U/kg to about 2,000 U/kg.
  • dosage and timing of EPO administration used in conjunction with a chemotherapeutic agent will depend upon the desired effect, as well as the chemotherapeutic agent utilized.
  • HUVECs Human umbilical vein endothelial cells
  • T-flasks Corning Inc., Corning, N.Y.
  • porcine skin gelatin Sigma Chemical Co., St. Louis, Mo.
  • Endothelial cells grown in the complete (supplemented) M199 medium were harvested in the log phase. At 80-90% confluency, EC culture monolayers were washed with phosphate buffered saline (PBS), treated with 0.25% trypsin in 1 mM EDTA for 1-2 minutes, and then the cells were suspended in complete medium. The number and viability of the cells was determined using a hemocytometer and the trypan blue staining, respectively. Cell suspensions of 7.22 ⁇ 10 4 cells/ml medium were prepared and 90 ⁇ l (6.5 ⁇ 10 3 cells) were dispensed into each well of a 96-well plate.
  • PBS phosphate buffered saline
  • EPO and/or the chemotherapeutic agent were added at concentrations and in the order specified in the examples described below. Plates were then incubated for another 24 hours. At the end of this incubation period, 20 ⁇ l of freshly prepared combined MTS/PMS (20:1 ratio) solution was added into each well and the plates were incubated for 1-4 more hours, as per manufacturer's recommendations. The absorbance of each well at 490 nm was recorded using an ELISA plate reader. The LD50 and the effect of the various treatments on cell viability and chemosensitivity were determined by plotting the corrected absorbance at 490 nm versus the concentration of the additive (EPO, chemotherapeutic agent, or combinations thereof).
  • the corrected absorbance at 490 nm versus the concentration of cisplatin ( ⁇ g/mL) was plotted (FIG. 1) to provide a dose-response curve.
  • the concentration of cisplatin required to give 50% of the maximal response (LD50 of cisplatin) was determined to be 0.45 ⁇ g/ml.
  • Endothelial cell cultures were prepared as described in Example 1. Cisplatin (final concentration of 1 ⁇ g/ml) was added to each test well simultaneously with 5 ⁇ l of various EPO preparations (final EPO concentration ranging from 0.15 to 20 U/ml. Endothelial cell viability was assessed using the MTS/PMS calorimetric assay described in Example 1. Results were compared to control wells (endothelial cells treated with 1 ⁇ g/ml cisplatin alone, considered as the baseline and represented in FIG. 2 as 0%). Results are provided in FIG.
  • the “% of control” is the percentage change of optical density at 490 nm over the control, such that “0” indicates the test well had similar numbers of metabolically active cells as the control, whereas “50%” indicates 50% more and “ ⁇ 50” indicates 50% fewer metabolically active cells.
  • endothelial cell growth was inhibited in cultures treated with from 5 to 20 U/ml of EPO when EPO was added simultaneously with cisplatin, compared to cultures treated with cisplatin alone.
  • Cultures treated with 5 U/ml of EPO and 1 ⁇ g/ml cisplatin showed a 33% decrease in the number of viable cells compared to control cells exposed to cisplatin alone.
  • Endothelial cell cultures were prepared as described in Example 1. Cisplatin was added to each test well (1 ⁇ g/ml final concentration of cisplatin); two hours later 5 ⁇ l of an EPO preparation ranging from 0.15 to 20 U/ml final concentration was added. Endothelial cell viability was assessed using the MTS/PMS calorimetric assay described in Example 1. Results were compared to control wells (endothelial cells treated with 1 ⁇ g/ml cisplatin alone).
  • Results are provided in FIG. 3, and show that a biphasic response was observed when EPO was added to cell cultures after the addition of cisplatin. Endothelial cell cultures treated with from 0.15 to 5 U/ml of EPO were protected from the damaging effects of cisplatin when EPO was added two hours following cisplatin exposure. The number of viable cells after treatment with 1.25 U/ml EPO after cisplatin exposure was 34% greater than that of controls. In contrast, cell viability in the presence of 10 to 20 U/ml EPO administered two hours after cisplatin exposure was reduced over that seen in controls (cisplatin only).
  • Endothelial cell cultures were prepared as described in Example 1. Each test well received 5 ⁇ l of an EPO preparation ranging from 0.15 to 20 U/ml EPO; two hours later cisplatin was added to each test well (5 ⁇ l of 1 ⁇ g/ml cisplatin). Endothelial cell viability was assessed using the MTS/PMS calorimetric assay described in Example 1. Results were compared to control wells (endothelial cells treated with 1 ⁇ g/ml cisplatin alone).
  • Results are provided in FIG. 4, and show a reduction in the number of viable endothelial cells after exposure to EPO two hours prior to cisplatin exposure (compared to control cells exposed only to cisplatin). Cell proliferation and viability was decreased by as much as 81% compared to controls. The inhibition was dose dependent; EPO concentrations as low as 5 and 2.5 U/ml reduced cell growth by 58% and 48%, respectively, compared to controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US08/712,358 1996-09-11 1996-09-11 Method of treating endothelial injury Abandoned US20020052309A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
US08/842,700 US5922674A (en) 1996-09-11 1997-04-15 Method of treatment using chemotherapy and erythropoietin
CA002265547A CA2265547C (en) 1996-09-11 1997-09-10 Method of treating endothelial injury
AT97940974T ATE282425T1 (de) 1996-09-11 1997-09-10 Verfahren zur behandlung von endothelialen verletzungen
PT97940974T PT933995E (pt) 1996-09-11 1997-09-10 Metodo para tratamento de lesao endotelial
HK00101826.8A HK1022810B (en) 1996-09-11 1997-09-10 Method of treating endothelial injury
PCT/US1997/015966 WO1998010650A1 (en) 1996-09-11 1997-09-10 Method of treating endothelial injury
JP10513794A JP2001503028A (ja) 1996-09-11 1997-09-10 内皮損傷の治療方法
ES97940974T ES2231889T3 (es) 1996-09-11 1997-09-10 Procedimiento de tratamiento de lesiones endoteliales.
DE69731652T DE69731652T2 (de) 1996-09-11 1997-09-10 Verfahren zur behandlung von endothelialen verletzungen
DK97940974T DK0933995T3 (da) 1996-09-11 1997-09-10 Fremgangsmåde til behandling af endotelskader
CN97199338A CN1113669C (zh) 1996-09-11 1997-09-10 治疗内皮创伤的方法
EP97940974A EP0933995B8 (en) 1996-09-11 1997-09-10 Method of treating endothelial injury
US09/525,797 US7531501B1 (en) 1996-09-11 2000-03-15 Method of treating endothelial injury
CNB021506884A CN1250281C (zh) 1996-09-11 2002-11-12 治疗内皮创伤的方法
US11/771,470 US7803408B2 (en) 1996-09-11 2007-06-29 Method of treating endothelial injury
JP2008048009A JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤
US12/509,841 US20090285908A1 (en) 1996-09-11 2009-07-27 Method of treating endothelial injury

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08/842,700 Division US5922674A (en) 1996-09-11 1997-04-15 Method of treatment using chemotherapy and erythropoietin
US52580800A Division 1996-09-11 2000-03-15
US09/525,797 Division US7531501B1 (en) 1996-09-11 2000-03-15 Method of treating endothelial injury

Publications (1)

Publication Number Publication Date
US20020052309A1 true US20020052309A1 (en) 2002-05-02

Family

ID=24861777

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/712,358 Abandoned US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
US08/842,700 Expired - Lifetime US5922674A (en) 1996-09-11 1997-04-15 Method of treatment using chemotherapy and erythropoietin
US09/525,797 Expired - Fee Related US7531501B1 (en) 1996-09-11 2000-03-15 Method of treating endothelial injury
US11/771,470 Expired - Fee Related US7803408B2 (en) 1996-09-11 2007-06-29 Method of treating endothelial injury
US12/509,841 Abandoned US20090285908A1 (en) 1996-09-11 2009-07-27 Method of treating endothelial injury

Family Applications After (4)

Application Number Title Priority Date Filing Date
US08/842,700 Expired - Lifetime US5922674A (en) 1996-09-11 1997-04-15 Method of treatment using chemotherapy and erythropoietin
US09/525,797 Expired - Fee Related US7531501B1 (en) 1996-09-11 2000-03-15 Method of treating endothelial injury
US11/771,470 Expired - Fee Related US7803408B2 (en) 1996-09-11 2007-06-29 Method of treating endothelial injury
US12/509,841 Abandoned US20090285908A1 (en) 1996-09-11 2009-07-27 Method of treating endothelial injury

Country Status (11)

Country Link
US (5) US20020052309A1 (enExample)
EP (1) EP0933995B8 (enExample)
JP (3) JP2001503028A (enExample)
CN (2) CN1113669C (enExample)
AT (1) ATE282425T1 (enExample)
CA (1) CA2265547C (enExample)
DE (1) DE69731652T2 (enExample)
DK (1) DK0933995T3 (enExample)
ES (1) ES2231889T3 (enExample)
PT (1) PT933995E (enExample)
WO (1) WO1998010650A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034799A1 (en) * 2002-07-03 2006-02-16 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs
US20070129293A1 (en) * 2003-09-29 2007-06-07 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US20080014193A1 (en) * 1999-04-13 2008-01-17 Michael Brines Modulation of excitable tissue function by peripherally administered erythropoietin
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
NZ514690A (en) * 1999-04-13 2004-07-30 Kenneth S Modulation of excitable tissue function by peripherally administered erythropoietin
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
BR0010316A (pt) * 1999-05-11 2004-04-27 Ortho Mcnell Pharmaceutical In Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
AU5462601A (en) * 2000-05-02 2001-11-12 Action Pharmaceuticals Aps Methods for treatment of diseases associated with inflammation under non-ischemic conditions
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1459762B1 (en) * 2001-11-02 2008-07-02 Yoshiko Yasuda Use of emp9 for the prevention of proliferative organ diseases
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2004317897B2 (en) * 2003-11-07 2010-04-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Activation of hypoxia-inducible gene expression
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US20050267027A1 (en) * 2004-04-05 2005-12-01 Lounsbury Karen M Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
IL308638A (en) * 2021-05-18 2024-01-01 Attias Eyal Use of erythropoietin or a substance that encourages erythropoiesis, to treat osteomyelitis and bone infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
AU4608296A (en) * 1994-12-30 1996-07-31 Chiron Corporation Methods and compositions for treatment of solid tumors in vivo
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US20080014193A1 (en) * 1999-04-13 2008-01-17 Michael Brines Modulation of excitable tissue function by peripherally administered erythropoietin
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20060034799A1 (en) * 2002-07-03 2006-02-16 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs
US8404226B2 (en) 2002-07-03 2013-03-26 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20070129293A1 (en) * 2003-09-29 2007-06-07 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

Also Published As

Publication number Publication date
CN1235512A (zh) 1999-11-17
US20090285908A1 (en) 2009-11-19
US7531501B1 (en) 2009-05-12
JP2009196999A (ja) 2009-09-03
CN1113669C (zh) 2003-07-09
CN1429623A (zh) 2003-07-16
EP0933995B8 (en) 2005-01-19
JP2001503028A (ja) 2001-03-06
DE69731652D1 (de) 2004-12-23
US5922674A (en) 1999-07-13
HK1022810A1 (en) 2000-08-25
WO1998010650A1 (en) 1998-03-19
PT933995E (pt) 2005-02-28
DE69731652T2 (de) 2005-12-15
JP2008133305A (ja) 2008-06-12
CN1250281C (zh) 2006-04-12
CA2265547C (en) 2009-12-01
CA2265547A1 (en) 1998-03-19
EP0933995A4 (en) 2002-08-28
US20080124401A1 (en) 2008-05-29
EP0933995A1 (en) 1999-08-11
ES2231889T3 (es) 2005-05-16
US7803408B2 (en) 2010-09-28
DK0933995T3 (da) 2005-02-14
ATE282425T1 (de) 2004-12-15
EP0933995B1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
US7803408B2 (en) Method of treating endothelial injury
Eschbach et al. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects
EP0346413B1 (en) Potentiation of erythropoiesis
WO2003037273A2 (en) Method of use of erythropoietin to treat ischemic acute renal failure
JP2010280672A (ja) エリスロポエチンの使用
US5824297A (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
RU2296563C2 (ru) Эритропоэтин облегчает in vivo токсичность, индуцированную химиотерапией
Wiedenmann et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas
AU2002256133A1 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
Lim et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency
JP2004500437A (ja) 可動化活性を有する調製物
EP0653211B1 (en) Blood coagulation normalizer containing tcf-ii as active ingredient
EP0588477A2 (en) Medicinal composition comprising TCF-II
US20080194490A1 (en) At4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
HK1022810B (en) Method of treating endothelial injury
CA2424297A1 (en) Human transferrin for the treatment of anemia of chronic disease (acd) and of functional iron deficiency
Okada et al. Pathophysiology of Shock: SYMPOSIUM ON TREATMENT OF SHOCK
Oettle et al. Recombinant human erythropoietin in the treatment of head and neck tumour anaemia
EP1930023A2 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
Tsuda et al. The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study
Koschinsky et al. Vascular growth factors and atherogenesis in diabetes mellitus
Haller The endothelium and the pathogenesis of chronic vascular diseases: The protective role of calcium antagonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: EAST CAROLINA UNIVERSITY, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANAGNOSTOU, ATHANASIUS A.;SIGOUNAS, GEORGE;REEL/FRAME:008272/0356

Effective date: 19961211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION